Selecta Biosciences (NASDAQ:SELB – Get Free Report) and Vectura Group (OTCMKTS:VEGPF – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.
Profitability
This table compares Selecta Biosciences and Vectura Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Selecta Biosciences | -18.21% | -17.67% | -8.81% |
| Vectura Group | N/A | N/A | N/A |
Risk and Volatility
Selecta Biosciences has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Vectura Group has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.
Institutional and Insider Ownership
Analyst Ratings
This is a breakdown of recent ratings and target prices for Selecta Biosciences and Vectura Group, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Selecta Biosciences | 0 | 0 | 4 | 0 | 3.00 |
| Vectura Group | 0 | 0 | 0 | 0 | N/A |
Selecta Biosciences presently has a consensus price target of $5.75, suggesting a potential upside of 422.73%. Given Selecta Biosciences’ higher probable upside, equities analysts clearly believe Selecta Biosciences is more favorable than Vectura Group.
Earnings & Valuation
This table compares Selecta Biosciences and Vectura Group’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Selecta Biosciences | $110.78 million | 1.52 | $35.38 million | ($0.09) | -12.22 |
| Vectura Group | $244.76 million | 4.37 | $157.16 million | $0.26 | 6.81 |
Vectura Group has higher revenue and earnings than Selecta Biosciences. Selecta Biosciences is trading at a lower price-to-earnings ratio than Vectura Group, indicating that it is currently the more affordable of the two stocks.
Summary
Vectura Group beats Selecta Biosciences on 8 of the 13 factors compared between the two stocks.
About Selecta Biosciences
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
About Vectura Group
Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
